Orogen Therapeutics Announces Expansion of Leadership Team with Appointment of CEO and Senior Medicinal Chemist
April 16, 2025
WOBURN,MA, April 16, 2025 – Orogen Therapeutics, Inc., a private drug discovery company utilizing its proprietary, AI-enabled DNA encoded library (DEL) technology to identify novel chemical matter against medically- and commercially-attractive drug targets, today announced Mark Pykett, PhD, VMD, MBA, as Chief Executive Officer and a member of the Board of Directors, and Dominque Potin, PhD, as Senior Principal Scientist in medicinal chemistry.
Read More »
Orogen Therapeutics Announces Expansion of Board with Biopharma Leaders Mikael Dolsten and Dieter Weinand as Independent Non-Executive Directors
May 16, 2025
WOBURN, MA, May 16, 2025 – Orogen Therapeutics, Inc., a private drug discovery company utilizing its proprietary, AI-enabled DNA encoded library (DEL) technology to identify novel chemical matter against medically and commercially attractive drug targets, today announced the expansion of its Board of Directors with Independent Non-Executive biopharma leaders Mikael Dolsten, M.D., Ph.D., prior Chief Scientific Officer and President of Research and Development at Pfizer, and Dieter Weinand, M.S., former CEO and chairman of the board of Bayer Pharmaceuticals AG.
Read More »